Charles River Laboratories is experiencing a notable rally, driven by a rebound in biotechnology funding, which has positively impacted its core contract research organization business. Following the release of its second-quarter earnings, which exceeded analyst expectations with earnings of $3.02 per share and revenue of $1 billion, the stock surged over 11%.
JPMorgan's analyst Casey Woodring highlighted a strong 1.19 book-to-bill ratio in the Discovery and Safety Assessment segment, indicating sustainable momentum supported by increased biotech funding and activity from large pharmaceutical companies. The firm raised its 12-month price target for Charles River from $180 to $310, suggesting a potential upside of 19% from its recent closing price.
Additionally, the company has increased its earnings forecast for 2026 to a range of $11.15 to $11.45 per share, reflecting confidence in continued growth. Overall, 14 out of 19 analysts covering the stock rate it as a buy or strong buy, aligning with JPMorgan's optimistic outlook